Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company focuses on therapies for neurological and endocrine diseases and disorders.

The company endured a significant setback on May 15, 2006 when the Food and Drug Administration (FDA) denied approval for the 15-milligram dose of Indiplon, a medication to treat insomnia. Neurocrine had developed the drug with its former partner, Pfizer.

Companies listed on NASDAQ | Companies in the NASDAQ Biotechnology Index | Biotechnology companies